Matches in Wikidata for { <http://www.wikidata.org/entity/Q100760857> ?p ?o ?g. }
Showing items 1 to 56 of
56
with 100 items per page.
- Q100760857 description "2020 ވަނަ އަހަރުގެ އޮކްޓޯބަރުމަހުގެ 21ވަނަ ދުވަހު ޝާއިރުކުރެވުނު ލިޔުމެއް" @default.
- Q100760857 description "article scientifique publié en 2020" @default.
- Q100760857 description "artículu científicu espublizáu n'ochobre de 2020" @default.
- Q100760857 description "scientific article published on 21 October 2020" @default.
- Q100760857 description "wetenschappelijk artikel" @default.
- Q100760857 description "наукова стаття, опублікована 21 жовтня 2020" @default.
- Q100760857 name "Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared to Standard Concurrent Treatment in Pre-clinical Models of Pancreatic Cancer" @default.
- Q100760857 name "Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared to Standard Concurrent Treatment in Pre-clinical Models of Pancreatic Cancer" @default.
- Q100760857 name "Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared to Standard Concurrent Treatment in Pre-clinical Models of Pancreatic Cancer" @default.
- Q100760857 type Item @default.
- Q100760857 label "Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared to Standard Concurrent Treatment in Pre-clinical Models of Pancreatic Cancer" @default.
- Q100760857 label "Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared to Standard Concurrent Treatment in Pre-clinical Models of Pancreatic Cancer" @default.
- Q100760857 label "Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared to Standard Concurrent Treatment in Pre-clinical Models of Pancreatic Cancer" @default.
- Q100760857 prefLabel "Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared to Standard Concurrent Treatment in Pre-clinical Models of Pancreatic Cancer" @default.
- Q100760857 prefLabel "Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared to Standard Concurrent Treatment in Pre-clinical Models of Pancreatic Cancer" @default.
- Q100760857 prefLabel "Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared to Standard Concurrent Treatment in Pre-clinical Models of Pancreatic Cancer" @default.
- Q100760857 P1433 Q100760857-DFFDD6A8-ADFC-4E07-8794-F297BBE0B0FA @default.
- Q100760857 P1476 Q100760857-BD16525E-9E9B-43E9-AFCA-18D7FC6A5EA3 @default.
- Q100760857 P2093 Q100760857-000CBA98-0083-4253-B45A-21F8C8E2D84A @default.
- Q100760857 P2093 Q100760857-3FA41448-5E86-4CFA-88AA-EE3FE006DA7E @default.
- Q100760857 P2093 Q100760857-40001F42-207B-46AB-B1CC-323B9F3F0E0F @default.
- Q100760857 P2093 Q100760857-4D30A496-C413-4DDC-BCE9-ABCCD46E8F67 @default.
- Q100760857 P2093 Q100760857-50CC230D-338F-4E93-93B9-25A2B3534144 @default.
- Q100760857 P2093 Q100760857-79E85795-68DD-4825-A5F3-0D2396D50AE3 @default.
- Q100760857 P2093 Q100760857-7B2C53A9-1436-4D54-A5D2-26F9C437555B @default.
- Q100760857 P2093 Q100760857-864F159A-5A43-4A85-BB95-102F16272717 @default.
- Q100760857 P2093 Q100760857-B0990687-C8C1-4813-8A72-6A60500352B2 @default.
- Q100760857 P2093 Q100760857-C57B05C2-3A71-4254-8C40-B4FF21C7E723 @default.
- Q100760857 P31 Q100760857-D516C061-5250-4680-8897-AE641082FB0E @default.
- Q100760857 P356 Q100760857-B991ADE2-4FAE-4780-A59F-EF699BD272B4 @default.
- Q100760857 P50 Q100760857-2C741DAB-230D-4FFA-9393-6048BFF177CD @default.
- Q100760857 P50 Q100760857-A91E5E25-DD62-4A66-9C35-E361C0BBF865 @default.
- Q100760857 P577 Q100760857-311FF2E9-0CDB-413A-B75A-DFD7A2873A94 @default.
- Q100760857 P698 Q100760857-D2A0CCE0-B26C-422F-B3D7-E536D3CC79C8 @default.
- Q100760857 P921 Q100760857-40F95801-D8A9-4FBE-B9C7-33D3CBA9EDFA @default.
- Q100760857 P356 1078-0432.CCR-20-1422 @default.
- Q100760857 P698 33087331 @default.
- Q100760857 P1433 Q332253 @default.
- Q100760857 P1476 "Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared to Standard Concurrent Treatment in Pre-clinical Models of Pancreatic Cancer" @default.
- Q100760857 P2093 "Ahmad Hegazi" @default.
- Q100760857 P2093 "Arnab Chakravarti" @default.
- Q100760857 P2093 "Duan-Liang Shyu" @default.
- Q100760857 P2093 "John R Jacob" @default.
- Q100760857 P2093 "Jose G Trevino" @default.
- Q100760857 P2093 "Kamalakannan Palanichamy" @default.
- Q100760857 P2093 "Laith Abushahin" @default.
- Q100760857 P2093 "Linlin Yang" @default.
- Q100760857 P2093 "Ryan Robb" @default.
- Q100760857 P2093 "Zobeida Cruz-Monserrate" @default.
- Q100760857 P31 Q13442814 @default.
- Q100760857 P356 "10.1158/1078-0432.CCR-20-1422" @default.
- Q100760857 P50 Q91299154 @default.
- Q100760857 P50 Q94949750 @default.
- Q100760857 P577 "2020-10-21T00:00:00Z" @default.
- Q100760857 P698 "33087331" @default.
- Q100760857 P921 Q212961 @default.